<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634253</url>
  </required_header>
  <id_info>
    <org_study_id>17424</org_study_id>
    <secondary_id>J1A-MC-KDAD</secondary_id>
    <secondary_id>2020-002673-10</secondary_id>
    <nct_id>NCT04634253</nct_id>
  </id_info>
  <brief_title>A Study of LY3462817 in Participants With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug LY3462817 is safe and effective in&#xD;
      participants with moderately to severely active rheumatoid arthritis (RA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 13, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline on the Disease Activity Score Modified to Include the 28 Diarthrodial Joint Count-High-Sensitivity C-Reactive Protein (DAS28-hsCRP)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>DAS28 consists of a composite score of the following variables: tender joint count out of 28 (TJC28), swollen joint count out of 28 (SJC28), hsCRP [milligrams per liter (mg/L)], and Patient's Global Assessment of Disease Activity (PaGADA_VAS) on a 0 to 100 millimeter (mm) VAS (0=very well to 100=very poor). A decrease in DAS28-CRP indicates an improvement in participant's condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20), (ACR50) and (ACR70)</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR responders are participants with at least 20%, 50% and 70% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measures participants perceived degree of difficulty performing daily activities, acute phase reactant as measured by hsCRP, Patient's Assessment of Pain-Visual Analog Scale (Pain-VAS), Patient's Global Assessment of Disease Activity (PaGADA_VAS), and Physician's Global Assessment of Disease Activity (PhGADA_VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline for Mean Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SDAI is the numerical sum of 5 outcome parameters: TJC28, SJC28, patient and physician global assessment of disease activity and CRP. Lower SDAI values indicate lower disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline for Mean Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The CDAI measures disease activity in RA. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-100 mm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-100 mm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. Lower CDAI scores indicate lower disease activity. A negative change from baseline indicates improvement in condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the 36 Item Short Form Health Survey (SF-36)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SF-36 is a health-related survey that assesses participant's health status and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health, mental health, social functioning, and vitality. The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Observed Concentration of LY3462817</measure>
    <time_frame>Week 12</time_frame>
    <description>PK: Observed Concentration of LY3462817</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>LY3462817 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3462817 given intravenously (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3462817 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3462817 given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given IV.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3462817</intervention_name>
    <description>Given IV</description>
    <arm_group_label>LY3462817 High Dose</arm_group_label>
    <arm_group_label>LY3462817 Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of adult onset RA as defined by the 2010 American College of&#xD;
             Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria&#xD;
             for at least 3 months prior to screening&#xD;
&#xD;
          -  Have moderately to severely active RA defined by the presence of ≥6 swollen joints&#xD;
             (based on 66 joint count) and ≥6 tender joints (based on 68 joint count) at screening&#xD;
             and baseline. The distal interphalangeal joint should be evaluated but not included in&#xD;
             the total count to determine eligibility&#xD;
&#xD;
          -  Have at least 1 of the following:&#xD;
&#xD;
               -  positive test results for rheumatoid factor or anti-citrullinated peptide&#xD;
                  antibodies at screening, OR&#xD;
&#xD;
               -  previous radiographs documenting bony erosions in hands or feet consistent with&#xD;
                  RA&#xD;
&#xD;
          -  Have C-reactive protein (CRP) &gt;1.2 times upper limit of normal (ULN) per the central&#xD;
             laboratory at screening&#xD;
&#xD;
          -  Demonstrated an inadequate response to, or loss of response or intolerance to:&#xD;
&#xD;
               -  at least 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD)&#xD;
                  treatment OR&#xD;
&#xD;
               -  at least 1 biologic DMARD/tsDMARD treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Class IV RA according to ACR revised response criteria&#xD;
&#xD;
          -  Have a diagnosis or history of malignant disease within 5 years prior to baseline,&#xD;
             with the exceptions of:&#xD;
&#xD;
               -  basal cell or squamous epithelial carcinomas of the skin that have been resected&#xD;
                  with no evidence of metastatic disease for 3 years, or&#xD;
&#xD;
               -  cervical carcinoma in situ, with no evidence of recurrence within the 5 years&#xD;
                  prior to baseline&#xD;
&#xD;
          -  Have presence of confirmed cervical dysplasia&#xD;
&#xD;
          -  Have had various types of infection within 3 months of screening or develops any of&#xD;
             these infections before the randomization visit.&#xD;
&#xD;
          -  Have any of the following:&#xD;
&#xD;
               -  Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
               -  Current infection with hepatitis B virus (HBV) (i.e., positive for hepatitis B&#xD;
                  surface antigen and/or polymerase chain reaction (PCR) positive for HBV DNA&#xD;
&#xD;
               -  Current infection with hepatitis C virus (HCV) (i.e., positive for HCV RNA)&#xD;
&#xD;
               -  Active tuberculosis (TB)&#xD;
&#xD;
          -  Have failed more than 2 biologic DMARDs (bDMARDs) or tsDMARDs (e.g. excluded if have&#xD;
             received 2 bDMARDs and 1 tsDMARD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates, P. C.</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>480-321-8558</phone>
    </contact>
    <investigator>
      <last_name>Swati Bharadwaj</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates, P. C.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-386-4970</phone>
    </contact>
    <investigator>
      <last_name>Mona Amin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>760-341-9638</phone>
    </contact>
    <investigator>
      <last_name>Maria Greenwald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology &amp; Osteoporosis Medical Group</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>909-296-8700</phone>
    </contact>
    <investigator>
      <last_name>Antony C. Hou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>402-420-1212</phone>
    </contact>
    <investigator>
      <last_name>Melvin A Churchill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>440-826-0742</phone>
    </contact>
    <investigator>
      <last_name>Isam A Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Research of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-702-6770</phone>
    </contact>
    <investigator>
      <last_name>Christine Codding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8146930300</phone>
    </contact>
    <investigator>
      <last_name>Alan Jan Kivitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Plus</name>
      <address>
        <city>Uherske Hradiste</city>
        <state>Zlínský Kraj</state>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00420572551850</phone>
    </contact>
    <investigator>
      <last_name>Eva Dokoupilova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PV Medical Services s.r.o.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00420577221686</phone>
    </contact>
    <investigator>
      <last_name>Petr Vitek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Kft.</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abaúj-Zemplén</state>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0036309635205</phone>
    </contact>
    <investigator>
      <last_name>Katalin Fazekas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Revita Clinic</name>
      <address>
        <city>Budapest</city>
        <state>Pest</state>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>003612016948</phone>
    </contact>
    <investigator>
      <last_name>Regina Maria Cseuz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vital Medical Center</name>
      <address>
        <city>Veszprem</city>
        <state>Veszprém City</state>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>003688790434</phone>
    </contact>
    <investigator>
      <last_name>Edit Drescher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0036302995005</phone>
    </contact>
    <investigator>
      <last_name>Bernadette Rojkovich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0036304226939</phone>
    </contact>
    <investigator>
      <last_name>Eszter Simoncsics</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Medico del Angel</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California</state>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>526865529404</phone>
    </contact>
    <investigator>
      <last_name>Beatriz Elena Zazueta Montiel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RM Pharma Specialists S.A. de C.V.</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>5526635163</phone>
    </contact>
    <investigator>
      <last_name>Jaime Reyes Gonzaga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigacion Basica y Clinica, S.C.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+523336165859107</phone>
    </contact>
    <investigator>
      <last_name>Ignacio Garcia Valladares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Köhler &amp; Milstein Research</name>
      <address>
        <city>Mérida</city>
        <state>Yucatan</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>529999204004</phone>
    </contact>
    <investigator>
      <last_name>Jesus Abraham Simon Campos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigacion y Biomedicina de Chihuahua</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>526144155012</phone>
    </contact>
    <investigator>
      <last_name>Cesar Francisco Pacheco-Tena</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Reumatologii i Ukladowych Chorob Tkanki Lacznej</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0048523655731</phone>
    </contact>
    <investigator>
      <last_name>Rafal Wojciechowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia Centrum Medyczne Nowa Sol</name>
      <address>
        <city>Nowa Sol</city>
        <state>Lubuskie</state>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0048684177519</phone>
    </contact>
    <investigator>
      <last_name>Malgorzata Miakisz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatika - Centrum Reumatologii</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0048221881112</phone>
    </contact>
    <investigator>
      <last_name>Janusz Jaworski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nzoz Bif-Med</name>
      <address>
        <city>Bytom</city>
        <state>Śląskie</state>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0048508270636</phone>
    </contact>
    <investigator>
      <last_name>Hanna Mastalerz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Reumatologico Caguas</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7874471491</phone>
    </contact>
    <investigator>
      <last_name>AMARILIS J PEREZ DE JESUS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Latin Clinical Trial Center</name>
      <address>
        <city>San Juan</city>
        <zip>909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7872494763</phone>
    </contact>
    <investigator>
      <last_name>Carlos A Pantojas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/5XEBVhZJQJiPOegLRVANvY</url>
    <description>A Study of LY3462817 in Participants With Rheumatoid Arthritis</description>
  </link>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting</ipd_time_frame>
    <ipd_access_criteria>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

